Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
11 Novembro 2024 - 3:46PM
AllPennyStocks.com
This late-stage clinical trial company focuses on preventing
inflammation and acute organ injury. It is developing a platform of
new drugs to prevent inflammation in the kidneys, liver and
lungs...
To read the full story on AllPennyStocks.com, click
here.
Arch Biopartners (TSXV:ARCH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Arch Biopartners (TSXV:ARCH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025